Trooskin S Z, Harvey R A, Lennard T W, Greco R S
Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, New Brunswick 08903.
Perit Dial Int. 1990;10(1):57-9.
Previous in vitro, in vivo, and a preliminary clinical report have demonstrated efficacy of noncovalently bonding antibiotics to the surface of continuous ambulatory peritoneal dialysis (CAPD) catheters in decreasing infectious complications. A larger prospective randomized clinical trial was completed. Eighty-six patients with chronic renal failure were enrolled in the study and randomized to receive either a surfactant treated or untreated control catheter. All catheters were soaked in cefoxitin at the time of insertion. Groups were comparable in terms of pre-existing illnesses, age, and gender. No differences were shown in the incidence of catheter-tract infections, peritonitis or mechanical complications. There was also no differences in microbiologic culture results. Therefore, it is concluded that this clinical trial did not demonstrate a reduction in catheter-related infectious complications by antibiotic bonding.
先前的体外、体内研究以及一份初步临床报告已证明，将抗生素非共价结合至持续性非卧床腹膜透析（CAPD）导管表面可有效减少感染并发症。一项更大规模的前瞻性随机临床试验已完成。86例慢性肾衰竭患者纳入该研究，并随机分为接受表面活性剂处理导管组或未处理的对照导管组。所有导管在插入时均浸泡于头孢西丁中。两组在既往疾病、年龄和性别方面具有可比性。导管出口感染、腹膜炎或机械并发症的发生率无差异。微生物培养结果也无差异。因此，得出结论，该临床试验未证明抗生素结合可减少导管相关感染并发症。
